BioPharma Today

Coming In Wednesday's "The Pink Sheet" DAILY - Optimer Looks To Expand Dificid Market

Optimer looks at prophylaxis as possible indication to expand market for newly approved Dificid to treat Clostridium difficile.

Latest News From "The Pink Sheet" DAILY - Potential New Incentives For Certain Drug Candidates

"Dormant" Drug Candidates Eligible For Exclusivity Incentives In Draft Bill

Bill floated by the National Health Council would promote development of therapies that have the potential to address an unmet medical need but are viewed by the biopharma industry as unattractive candidates because they have insufficient patent protection.   read more

Editors' Picks from the World Press

Pipeline/RD News

• Trial finds RoActemra effective as stand-alone RA therapy
• ARCA will advance heart drug Gencaro to late-stage trial

Business Finance

• Drug shortage is getting worse
• AstraZeneca stops sponsoring doctors' foreign trips amid scrutiny
• Mylan unveils strategy for continued Indian expansion
• JJ's biopharma business is overlooked, analyst says

Government Legal News

• FDA approves Teva's generic of HIV drug Combivir
• Oceana receives FDA approval for fecal-incontinence drug
• FDA approves Optimer's Dificid to treat C. difficile infection
• Somaxon sues Par again regarding sleeping drug Silenor

Coming in Monday's "The Pink Sheet" DAILY

Genentech will be allowed to present details about its proposal for a new confirmatory trial of Avastin in metastatic breast cancer at a June FDA hearing on the future of the indication.

Latest News From "The Pink Sheet" DAILY - Study Calls HDL Hypothesis Into Question

More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit

NIH's early termination of the AIM-HIGH trial does further damage to combination therapy for increasing HDL cholesterol and lowering triglycerides in patients with well-controlled LDL cholesterol.   read more

Editors' Picks from the World Press

 

Pipeline/RD News

• NIH study questions Niaspan's benefit for heart patients

Coming In Friday's "The Pink Sheet" DAILY - Lilly Sales Reps Are Blocked From Promoting Boehringer's Tradjenta

Pfizer Inc. unveiled a new outsourcing model for drug development May 26, three months after CEO Ian Read announced sweeping budget cuts to the R&D organization. Under the new arrangement Pfizer will consolidate clinical trial implementation services from 17 service providers to two primary contract research organizations, Icon Plc and Parexel International Corporation.

Latest News From "The Pink Sheet" DAILY - E-Health Records Target Trial Recruiting

E-Health Records Effort Aims To Improve Clinical Trial Recruiting

New York state consortium is testing data mining methods that use digitized medical records to identify patients for clinical trials.   read more

Editors' Picks from the World Press

Pipeline/RD News

• Vivus touts success of ED drug avanafil in Phase III trial
• RA trial will compare UCB's Cimzia and Abbott's Humira
• Typical drug label warns of 70 adverse reactions, experts say

Business Finance

• Mylan markets a generic of painkiller Roxicodone
• Columbia tops a list of the most efficient drugmakers
• 4SC counts on trial data to find a partner for RA drug candidate
• Watson pays at least $562M to take over Greece's Specifar

Government Legal News

• EU is expected to reject Pharmaxis' CF drug Bronchitol
• Lawmakers also want Avanir to justify Nuedexta's price
• Sanofi paid experts to lobby against generic Lovenox, senators say

Coming In Thursday's "The Pink Sheet" DAILY - Elan, Proteostasis Team Up In Neurodisease Pact

Elan buys a 24% stake in Proteostasis through a $50 million dollar neurodegenerative drug discovery deal. Elan will fund R&D for the creation of new drugs based on Proteostasis’ development platform.